Avaliação do site lifescivc.com
LifeSciVC - Bruce Booth, partner at Atlas Venture, blogs on all facets of early stage biotech.LifeSciVC | Bruce Booth, partner at Atlas Venture, blogs on all facets of early stage biotech.
Gerado a 27 de Março de 2026 06:27 AM
Estatísticas desatualizadas? ATUALIZE !
O resultado é de 54/100
Conteúdo SEO
Título
LifeSciVC - Bruce Booth, partner at Atlas Venture, blogs on all facets of early stage biotech.LifeSciVC | Bruce Booth, partner at Atlas Venture, blogs on all facets of early stage biotech.
Cumprimento : 188
Idealmente, o Título deve conter entre 10 e 70 caracteres (incluíndo espaços).
Descrição
Bruce Booth, partner at Atlas Venture, blogs on all facets of early stage biotech.
Cumprimento : 82
Perfeito, a Descrição META contém entre 70 e 160 caracteres.
Palavras-chave
Mau. Não detetámos palavras-chave META na sua página.
Propriedades Og Meta
Boa! Esta página tira vantagens das propriedades Og.
| Propriedade | Conteúdo |
|---|---|
| locale | en_US |
| type | website |
| title | LifeSciVC |
| description | Bruce Booth, partner at Atlas Venture, blogs on all facets of early stage biotech. |
| url | https://lifescivc.com/ |
| site_name | LifeSciVC |
Cabeçalhos
| H1 | H2 | H3 | H4 | H5 | H6 |
| 2 | 40 | 7 | 0 | 0 | 0 |
- [H1] Process-Driven Cadence: Biotech IPOs Demystified
- [H1] Atlas Venture 2025 Year In Review
- [H2] Twenty Years In Early Stage Biotech VC (Part 3): BusinessOctober 16, 2025
- [H2] Twenty Years In Early Stage Biotech VC (Part 2): PeopleOctober 15, 2025
- [H2] Twenty Years In Early Stage Biotech VC (Part 1): ScienceOctober 14, 2025
- [H2] Biotech Wisdom Of The Crowds: Competition And CapitalismMay 28, 2025
- [H2] Biotech Venture Creation: The Benefits Of ScarcityApril 8, 2025
- [H2] Atlas XIV And Reflections On The VC Math ProblemDecember 5, 2024
- [H2] Atlas Venture 2024 Year In ReviewNovember 18, 2024
- [H2] Biotech Risk Cycles: Assets And PlatformsOctober 28, 2024
- [H2] A Molecular Biologist’s Advice For LifeJuly 1, 2024
- [H2] Mariana Oncology’s Radiopharm Platform Acquired By NovartisMay 6, 2024
- [H2] The Biotech Startup Contraction Continues… And That’s A Good ThingApril 26, 2024
- [H2] IFM’s Hat Trick and Reflections On Option-To-Buy M&AMarch 13, 2024
- [H2] Biotech Venture Ecosystem: Quick Health CheckJanuary 12, 2024
- [H2] Biotech Consolidation: Not Really HappeningNovember 30, 2023
- [H2] Atlas Venture 2023 Year In ReviewNovember 17, 2023
- [H2] Biotech Funding: Times Are Tough, Maybe For The BetterApril 14, 2023
- [H2] Science2Startup 2023: Innovation And EntrepreneurshipFebruary 28, 2023
- [H2] Takeda Acquires Nimbus’ Tyk2 Autoimmune ProgramDecember 13, 2022
- [H2] Atlas Venture 2022 Year In ReviewNovember 7, 2022
- [H2] Surprising Resilience Of Private VC-Backed Biotech MarketsJuly 6, 2022
- [H2] Responding To Tough Markets: Restructurings In BiotechApril 14, 2022
- [H2] Biotech’s January Chill: Big Drop In New StartupsApril 4, 2022
- [H2] In Defense Of Early Stage Biotech IPOsMarch 28, 2022
- [H2] Innovation Ecosystem: A Year Of Risk-Off CorrelationsMarch 21, 2022
- [H2] Biotech Bears: Jumping A Lower Bar Or A Higher One?March 17, 2022
- [H2] Getting Public Is Easy, Being Public Is HardNovember 18, 2021
- [H2] State of the Industry: 2021 Year In ReviewNovember 16, 2021
- [H2] Biotech’s Relevancy Challenge In An Expanding UniverseJune 1, 2021
- [H2] Five Macro Risks To Biotech Coming Out of WashingtonApril 22, 2021
- [H2] Biotech Funding Tops The Charts AgainApril 20, 2021
- [H2] Personal Reflection: Empathy In The WorkplaceMarch 16, 2021
- [H2] The Biotech Paradox of 2020: A Year In ReviewJanuary 4, 2021
- [H2] Biotech: The Featherweight Champion Of The MarketsNovember 20, 2020
- [H2] It’s Raining Biotech SPACs!October 15, 2020
- [H2] Evolution Of The Biotech IPO Markets From Busted To BoomingSeptember 21, 2020
- [H2] Kymera Debuts On The Public MarketsAugust 31, 2020
- [H2] The Record-Breaking Biotech Funding Tsunami Of 1H2020July 15, 2020
- [H2] Value Creation And Destruction: Dispersion of Performance In Biotech IPOsApril 17, 2020
- [H2] Booming VC-Backed Biopharma: Strong Market Despite PandemicApril 8, 2020
- [H2] Strategic Planning In Biotech During A Pandemic CrisisMarch 26, 2020
- [H3] search
- [H3] subscribe by email
- [H3] Twitter
- [H3] Recent Posts
- [H3] current comments
- [H3] topics
- [H3] monthly archive
Imagens
Encontrámos 9 imagens nesta página.
3 atributos ALT estão vazios ou em falta. É recomendado adicionar texto alternativo de modo a que os motores de busca identifiquem melhor o conteúdo das suas imagens.
Rácio Texto/HTML
Rácio : 17%
Bom! O rácio de texto para código HTML desta página é maior que 15, mas menor que 25 porcento.
Flash
Perfeito, não foi encontrado conteúdo Flash nesta página.
Iframe
Excelente, não foram detetadas Iframes nesta página.
Ligações SEO
Reescrita de URL
Perfeito. As ligações aparentam ser limpas!
Underscores (traços inferiores) nas URLs
Detetámos 'underscores' (traços inferiores) nas suas URLs. O uso hífens é mais eficiente em termos de otimização SEO.
Ligações para a própria página
Encontrámos um total de 289 ligações incluindo 0 ligações a ficheiros
| Âncoras | Tipo | Sumo |
|---|---|---|
| Blog | Internas | Passa sumo |
| About Me | Internas | Passa sumo |
| From The Trenches | Internas | Passa sumo |
| Process-Driven Cadence: Biotech IPOs Demystified | Internas | Passa sumo |
| Capital markets | Internas | Passa sumo |
| Exits IPOs M&As | Internas | Passa sumo |
| - | Externas | Passa sumo |
| - | Externas | Passa sumo |
| - | Externas | Passa sumo |
| - | Externas | Passa sumo |
| - | Externas | Passa sumo |
| how fundamentally it changed the IPO process | Internas | Passa sumo |
| Comment | Internas | Passa sumo |
| Atlas Venture 2025 Year In Review | Internas | Passa sumo |
| Atlas Venture | Internas | Passa sumo |
| Biotech financing | Internas | Passa sumo |
| Drug discovery | Internas | Passa sumo |
| Pharma industry | Internas | Passa sumo |
| Pricing and Policy | Internas | Passa sumo |
| R&D Productivity | Internas | Passa sumo |
| Science & Medicine | Internas | Passa sumo |
| - | Externas | Passa sumo |
| - | Externas | Passa sumo |
| - | Externas | Passa sumo |
| - | Externas | Passa sumo |
| - | Externas | Passa sumo |
| 2024 | Internas | Passa sumo |
| 2023 | Internas | Passa sumo |
| 2022 | Internas | Passa sumo |
| 2021 | Internas | Passa sumo |
| 2020 | Internas | Passa sumo |
| 2019 | Internas | Passa sumo |
| 2018 | Internas | Passa sumo |
| Comment | Internas | Passa sumo |
| Twenty Years In Early Stage Biotech VC (Part 3): Business | Internas | Passa sumo |
| Twenty Years In Early Stage Biotech VC (Part 2): People | Internas | Passa sumo |
| Twenty Years In Early Stage Biotech VC (Part 1): Science | Internas | Passa sumo |
| Biotech Wisdom Of The Crowds: Competition And Capitalism | Internas | Passa sumo |
| Biotech Venture Creation: The Benefits Of Scarcity | Internas | Passa sumo |
| Atlas XIV And Reflections On The VC Math Problem | Internas | Passa sumo |
| Biotech Risk Cycles: Assets And Platforms | Internas | Passa sumo |
| A Molecular Biologist’s Advice For Life | Internas | Passa sumo |
| Mariana Oncology’s Radiopharm Platform Acquired By Novartis | Internas | Passa sumo |
| The Biotech Startup Contraction Continues… And That’s A Good Thing | Internas | Passa sumo |
| IFM’s Hat Trick and Reflections On Option-To-Buy M&A | Internas | Passa sumo |
| Biotech Venture Ecosystem: Quick Health Check | Internas | Passa sumo |
| Biotech Consolidation: Not Really Happening | Internas | Passa sumo |
| Biotech Funding: Times Are Tough, Maybe For The Better | Internas | Passa sumo |
| Science2Startup 2023: Innovation And Entrepreneurship | Internas | Passa sumo |
| Takeda Acquires Nimbus’ Tyk2 Autoimmune Program | Internas | Passa sumo |
| Surprising Resilience Of Private VC-Backed Biotech Markets | Internas | Passa sumo |
| Responding To Tough Markets: Restructurings In Biotech | Internas | Passa sumo |
| Biotech’s January Chill: Big Drop In New Startups | Internas | Passa sumo |
| In Defense Of Early Stage Biotech IPOs | Internas | Passa sumo |
| Innovation Ecosystem: A Year Of Risk-Off Correlations | Internas | Passa sumo |
| Biotech Bears: Jumping A Lower Bar Or A Higher One? | Internas | Passa sumo |
| Getting Public Is Easy, Being Public Is Hard | Internas | Passa sumo |
| Biotech’s Relevancy Challenge In An Expanding Universe | Internas | Passa sumo |
| Five Macro Risks To Biotech Coming Out of Washington | Internas | Passa sumo |
| Biotech Funding Tops The Charts Again | Internas | Passa sumo |
| Personal Reflection: Empathy In The Workplace | Internas | Passa sumo |
| Biotech: The Featherweight Champion Of The Markets | Internas | Passa sumo |
| It’s Raining Biotech SPACs! | Internas | Passa sumo |
| Kymera Debuts On The Public Markets | Internas | Passa sumo |
| The Record-Breaking Biotech Funding Tsunami Of 1H2020 | Internas | Passa sumo |
| Value Creation And Destruction: Dispersion of Performance In Biotech IPOs | Internas | Passa sumo |
| Booming VC-Backed Biopharma: Strong Market Despite Pandemic | Internas | Passa sumo |
| Strategic Planning In Biotech During A Pandemic Crisis | Internas | Passa sumo |
| Tweets by @LifeSciVC | Externas | Passa sumo |
| Balancing the Risks and Rewards of Drug Development in China: A Small Biotech CEO Perspective | Internas | Passa sumo |
| Ex-US Clinical Trials: Tribulations, Preparations, and Expectations | Internas | Passa sumo |
| Dual Wielding in I&I: A Pivotal Year Ahead | Internas | Passa sumo |
| Why Owning the Learning Loop Matters More Than Owning the Lab | Internas | Passa sumo |
| Two’s Company, Three’s Diversity | Internas | Passa sumo |
| Two’s Company, Three’s Diversity | Internas | Passa sumo |
| AliFarquhar | Externas | Passa sumo |
| Two’s Company, Three’s Diversity | Internas | Passa sumo |
| When Does Digital Health Become Just Healthcare? | Internas | Passa sumo |
| We Saw It Coming In Pharma: Now Gene Therapy Is Biotech 2.0 For Rare Diseases | Internas | Passa sumo |
| #RunningAtlas | Internas | Passa sumo |
| Adaptive Sports | Internas | Passa sumo |
| Bioentrepreneurship | Internas | Passa sumo |
| Biotech investment themes | Internas | Passa sumo |
| Biotech startup advice | Internas | Passa sumo |
| Boards and governance | Internas | Passa sumo |
| Boston Cluster | Internas | Passa sumo |
| Business Development | Internas | Passa sumo |
| Capital efficiency | Internas | Passa sumo |
| China | Internas | Passa sumo |
| Corporate Culture | Internas | Passa sumo |
| Diagnostics | Internas | Passa sumo |
| External R&D | Internas | Passa sumo |
| FDA | Internas | Passa sumo |
| From The Trenches | Internas | Passa sumo |
| Fundraising | Internas | Passa sumo |
| General Venture Capital | Internas | Passa sumo |
| Governance | Internas | Passa sumo |
| Leadership | Internas | Passa sumo |
| Marketing | Internas | Passa sumo |
| New business models | Internas | Passa sumo |
| Patients | Internas | Passa sumo |
| Personal | Internas | Passa sumo |
| Personalized Medicine | Internas | Passa sumo |
| Portfolio news | Internas | Passa sumo |
| Rare Diseases | Internas | Passa sumo |
| Strategy | Internas | Passa sumo |
| Talent | Internas | Passa sumo |
| The Human Element | Internas | Passa sumo |
| Translational research | Internas | Passa sumo |
| Uncategorized | Internas | Passa sumo |
| VC-backed Biotech Returns | Internas | Passa sumo |
| March 2026 | Internas | Passa sumo |
| February 2026 | Internas | Passa sumo |
| January 2026 | Internas | Passa sumo |
| December 2025 | Internas | Passa sumo |
| November 2025 | Internas | Passa sumo |
| October 2025 | Internas | Passa sumo |
| September 2025 | Internas | Passa sumo |
| August 2025 | Internas | Passa sumo |
| July 2025 | Internas | Passa sumo |
| June 2025 | Internas | Passa sumo |
| May 2025 | Internas | Passa sumo |
| April 2025 | Internas | Passa sumo |
| March 2025 | Internas | Passa sumo |
| February 2025 | Internas | Passa sumo |
| January 2025 | Internas | Passa sumo |
| December 2024 | Internas | Passa sumo |
| November 2024 | Internas | Passa sumo |
| October 2024 | Internas | Passa sumo |
| September 2024 | Internas | Passa sumo |
| August 2024 | Internas | Passa sumo |
| July 2024 | Internas | Passa sumo |
| June 2024 | Internas | Passa sumo |
| May 2024 | Internas | Passa sumo |
| April 2024 | Internas | Passa sumo |
| March 2024 | Internas | Passa sumo |
| February 2024 | Internas | Passa sumo |
| January 2024 | Internas | Passa sumo |
| November 2023 | Internas | Passa sumo |
| October 2023 | Internas | Passa sumo |
| September 2023 | Internas | Passa sumo |
| August 2023 | Internas | Passa sumo |
| July 2023 | Internas | Passa sumo |
| June 2023 | Internas | Passa sumo |
| May 2023 | Internas | Passa sumo |
| April 2023 | Internas | Passa sumo |
| March 2023 | Internas | Passa sumo |
| February 2023 | Internas | Passa sumo |
| January 2023 | Internas | Passa sumo |
| December 2022 | Internas | Passa sumo |
| November 2022 | Internas | Passa sumo |
| October 2022 | Internas | Passa sumo |
| September 2022 | Internas | Passa sumo |
| August 2022 | Internas | Passa sumo |
| July 2022 | Internas | Passa sumo |
| June 2022 | Internas | Passa sumo |
| May 2022 | Internas | Passa sumo |
| April 2022 | Internas | Passa sumo |
| March 2022 | Internas | Passa sumo |
| February 2022 | Internas | Passa sumo |
| January 2022 | Internas | Passa sumo |
| November 2021 | Internas | Passa sumo |
| October 2021 | Internas | Passa sumo |
| September 2021 | Internas | Passa sumo |
| August 2021 | Internas | Passa sumo |
| July 2021 | Internas | Passa sumo |
| June 2021 | Internas | Passa sumo |
| May 2021 | Internas | Passa sumo |
| April 2021 | Internas | Passa sumo |
| March 2021 | Internas | Passa sumo |
| January 2021 | Internas | Passa sumo |
| December 2020 | Internas | Passa sumo |
| November 2020 | Internas | Passa sumo |
| October 2020 | Internas | Passa sumo |
| September 2020 | Internas | Passa sumo |
| August 2020 | Internas | Passa sumo |
| July 2020 | Internas | Passa sumo |
| June 2020 | Internas | Passa sumo |
| May 2020 | Internas | Passa sumo |
| April 2020 | Internas | Passa sumo |
| March 2020 | Internas | Passa sumo |
| February 2020 | Internas | Passa sumo |
| January 2020 | Internas | Passa sumo |
| December 2019 | Internas | Passa sumo |
| November 2019 | Internas | Passa sumo |
| October 2019 | Internas | Passa sumo |
| September 2019 | Internas | Passa sumo |
| August 2019 | Internas | Passa sumo |
| July 2019 | Internas | Passa sumo |
| May 2019 | Internas | Passa sumo |
| April 2019 | Internas | Passa sumo |
| March 2019 | Internas | Passa sumo |
| February 2019 | Internas | Passa sumo |
| January 2019 | Internas | Passa sumo |
| December 2018 | Internas | Passa sumo |
| November 2018 | Internas | Passa sumo |
| October 2018 | Internas | Passa sumo |
| September 2018 | Internas | Passa sumo |
| August 2018 | Internas | Passa sumo |
| July 2018 | Internas | Passa sumo |
| June 2018 | Internas | Passa sumo |
| May 2018 | Internas | Passa sumo |
| April 2018 | Internas | Passa sumo |
| March 2018 | Internas | Passa sumo |
| February 2018 | Internas | Passa sumo |
| January 2018 | Internas | Passa sumo |
| December 2017 | Internas | Passa sumo |
| November 2017 | Internas | Passa sumo |
| October 2017 | Internas | Passa sumo |
| September 2017 | Internas | Passa sumo |
| August 2017 | Internas | Passa sumo |
| July 2017 | Internas | Passa sumo |
| June 2017 | Internas | Passa sumo |
| May 2017 | Internas | Passa sumo |
| April 2017 | Internas | Passa sumo |
| March 2017 | Internas | Passa sumo |
| February 2017 | Internas | Passa sumo |
| January 2017 | Internas | Passa sumo |
| December 2016 | Internas | Passa sumo |
| November 2016 | Internas | Passa sumo |
| October 2016 | Internas | Passa sumo |
| September 2016 | Internas | Passa sumo |
| August 2016 | Internas | Passa sumo |
| July 2016 | Internas | Passa sumo |
| June 2016 | Internas | Passa sumo |
| May 2016 | Internas | Passa sumo |
| April 2016 | Internas | Passa sumo |
| March 2016 | Internas | Passa sumo |
| February 2016 | Internas | Passa sumo |
| January 2016 | Internas | Passa sumo |
| December 2015 | Internas | Passa sumo |
| November 2015 | Internas | Passa sumo |
| October 2015 | Internas | Passa sumo |
| September 2015 | Internas | Passa sumo |
| August 2015 | Internas | Passa sumo |
| July 2015 | Internas | Passa sumo |
| June 2015 | Internas | Passa sumo |
| May 2015 | Internas | Passa sumo |
| April 2015 | Internas | Passa sumo |
| March 2015 | Internas | Passa sumo |
| February 2015 | Internas | Passa sumo |
| January 2015 | Internas | Passa sumo |
| December 2014 | Internas | Passa sumo |
| November 2014 | Internas | Passa sumo |
| October 2014 | Internas | Passa sumo |
| September 2014 | Internas | Passa sumo |
| August 2014 | Internas | Passa sumo |
| July 2014 | Internas | Passa sumo |
| June 2014 | Internas | Passa sumo |
| May 2014 | Internas | Passa sumo |
| April 2014 | Internas | Passa sumo |
| March 2014 | Internas | Passa sumo |
| February 2014 | Internas | Passa sumo |
| January 2014 | Internas | Passa sumo |
| December 2013 | Internas | Passa sumo |
| November 2013 | Internas | Passa sumo |
| October 2013 | Internas | Passa sumo |
| September 2013 | Internas | Passa sumo |
| August 2013 | Internas | Passa sumo |
| July 2013 | Internas | Passa sumo |
| June 2013 | Internas | Passa sumo |
| May 2013 | Internas | Passa sumo |
| April 2013 | Internas | Passa sumo |
| March 2013 | Internas | Passa sumo |
| February 2013 | Internas | Passa sumo |
| January 2013 | Internas | Passa sumo |
| December 2012 | Internas | Passa sumo |
| November 2012 | Internas | Passa sumo |
| October 2012 | Internas | Passa sumo |
| September 2012 | Internas | Passa sumo |
| August 2012 | Internas | Passa sumo |
| July 2012 | Internas | Passa sumo |
| June 2012 | Internas | Passa sumo |
| May 2012 | Internas | Passa sumo |
| April 2012 | Internas | Passa sumo |
| March 2012 | Internas | Passa sumo |
| February 2012 | Internas | Passa sumo |
| January 2012 | Internas | Passa sumo |
| December 2011 | Internas | Passa sumo |
| November 2011 | Internas | Passa sumo |
| October 2011 | Internas | Passa sumo |
| September 2011 | Internas | Passa sumo |
| August 2011 | Internas | Passa sumo |
| July 2011 | Internas | Passa sumo |
| June 2011 | Internas | Passa sumo |
| May 2011 | Internas | Passa sumo |
| April 2011 | Internas | Passa sumo |
| March 2011 | Internas | Passa sumo |
| Privacy Policy | Internas | Passa sumo |
Palavras-chave SEO
Núvem de palavras-chave
april november biotech january year comment venture march leave ipo
Consistência das Palavras-chave
| Palavra-chave | Conteúdo | Título | Palavras-chave | Descrição | Cabeçalhos |
|---|---|---|---|---|---|
| biotech | 42 |  |
 |
|
|
| ipo | 28 | |
|
|
|
| comment | 22 | |
|
|
|
| leave | 22 | |
|
|
|
| april | 21 | |
|
|
|
Usabilidade
Url
Domínio : lifescivc.com
Cumprimento : 13
Favicon
Ótimo, o site tem um favicon.
Facilidade de Impressão
Não encontrámos CSS apropriado para impressão.
Língua
Otimo! A língua declarada deste site é en.
Dublin Core
Esta página não tira vantagens do Dublin Core.
Documento
Tipo de Documento
HTML 5
Codificação
Perfeito. O conjunto de caracteres UTF-8 está declarado.
Validação W3C
Erros : 0
Avisos : 0
Privacidade do Email
Aviso! No mínimo, foi encontrado um endereço de email sob a forma de texto. Isto é um convite para que spammers entupam a caixa de correio deste endereço.
HTML obsoleto
Fantástico! Não detetámos etiquetas HTML obsoletas.
Dicas de Velocidade
|
Excelente, este site não usa tablelas dentro de tabelas. |
|
Oh não, o site usa estilos CSS nas etiquetas HTML. |
|
Oh, não! O site utiliza demasiados ficheiros CSS (mais que 4). |
|
Oh, não! O site utiliza demasiados ficheiros JavaScript (mais que 6). |
|
Perfeito, o site tira vantagens da compressão gzip. |
Dispositivos Móveis
Otimização para dispositivos móveis
|
Icon Apple |
|
Meta Viewport Tag |
|
Conteúdo Flash |
Otimização
XML Sitemap
Perfeito, o site tem um mapa XML do site (sitemap).
| https://lifescivc.com/sitemap_index.xml |
Robots.txt
https://lifescivc.com/robots.txt
Perfeito, o seu site tem um ficheiro robots.txt.
Analytics
Perfeito, o site tem uma ferramenta analítica para a análise de atividade.
Google Analytics |
PageSpeed Insights
Dispositivo
Categorias
Free SEO Testing Tool
Free SEO Testing Tool é uma ferramenta gratuita que o ajuda a avaliar o seu site